User shared 12-month hair loss progress using oral minoxidil, oral dutasteride, and 2% ketoconazole shampoo. They detailed their medication regimen and dosages.
The user experienced significant hair thinning in two months and is questioning if this is typical of male pattern baldness. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.
A man in his late twenties switched from finasteride to dutasteride for hair loss and is sharing his 3-month progress, noting increased shedding but no side effects. Some responders think the treatment is working.
How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.
The user experienced hair regrowth after using finasteride for three months and microneedling with a dermapen for a month and a half. Many responses confirm noticeable hair thickening, though some suggest waiting longer for more definitive results.
The conversation is about whether the Ordinary's Multi-Peptide Serum for hair density can be mixed with finasteride. A video was mentioned that shows the serum being mixed with Stemoxydine.
A 30-year-old male has been on finasteride/dutasteride for 3 years, with stable but still receding hairline, and blood tests showing high total testosterone but normal DHT and free testosterone levels. Despite challenges in gaining muscle, he maintains a good physique with a consistent lifting routine and recently improved results with creatine.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.